Alpha Tau’s Alpha DaRT shows safety and efficacy in multiple trials

Alpha Tau reported initial long-term safety and tumor control outcomes of alpha-radiation cancer therapy Alpha DaRT for patients with unresectable, recurrent, or locally advanced head and neck or skin tumors across four prospective trials. Between February 2017 and December 2022, 81 lesions in 71 patients were treated with Alpha DaRT in four prospective feasibility trials whose objective was to assess early toxicity and tumor response outcomes. A complete response was observed in 89% of treated lesions, 10% demonstrated a partial response, and one patient was not evaluable. – Two-year local recurrence-free survival rate was 77%. 20% of patients developed treatment-related acute grade 2 toxicity such as dermatitis radiation, local pain at the treatment site or pruritus, which subsequently resolved with conservative treatment; there were no grade 3 or higher related acute toxicities. There was no grade 2 or higher late toxicities observed in this cohort, defined as toxicities occurring six months or later after Alpha DaRT treatment.